CTRI/2013/08/003921
Completed
Phase 3
A Randomized, Multiple-dose, Multicenter, Comparative Parallel Study To Evaluate The Efficacy, Safety And Pharmacokinetic Characteristics Of Intravenous Infusion Of Rituximab (Hetero) And Reference Medicinal Product (Rituximab, Roche) In Indian Patients Of Non-Hodgkins Lymphoma (HERILY Study)
Overview
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Hetero Drugs Limited
- Enrollment
- 150
- Locations
- 36
- Primary Endpoint
- Overall Response rate (ORR) by International Working Group (IWG) response criteria
Overview
Brief Summary
This study is an open label, randomized, multiple-dose, parallel study to evaluate the safety and efficacy of intravenous infusion of Rituximab Test product (Hetero) and Reference product in two clinical subtypes of Non-Hodgkin’s lymphoma (DLBCL & follicular) given along with CHOP chemotherapy. The primary objective is to compare the antitumor efficacy of Hetero-Rituximab with Reference Medicinal Product (Rituximab, Roche). The secondary objectives are to evaluate safety of the patients, compare the immunogenic potentials from baseline to the end of 3rd & 6thcycles of chemotherapy, to evaluate the pharmacokinetic characteristics at 1st & 6th cycles of chemotherapy, and compare the pharmacodynamics from baseline to the end of 3rd & 6th cycles of chemotherapy, between two formulations of Rituximab (test and reference).
Study Design
- Study Type
- Interventional
- Allocation
- Computer generated randomization
- Masking
- Open Label
Eligibility Criteria
- Ages
- 18.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •â€¢The patient willing to give written, signed, and dated informed consent to participate in the study before initiating any study related procedures •Male or Female ≥18 years and ≤65 years of age (both inclusive) •Histologically confirmed CD20-positive- Newly diagnosed diffuse large B-cell Non-Hodgkin’s lymphoma OR Previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy •Patients who are eligible for rituximab and CHOP •Patients with at least one measurable lesion as per International Working Group Response Criteria for Malignant Lymphoma •Adequate liver, renal, cardiac and haematological functions •Subjects with a performance status of 0 to 2 according to the Eastern Cooperative Oncology Group (ECOG) •Life expectancy more than six months •No other serious illness that according to investigator might jeopardize the well-being, the safety of study subjects, the compliance to study medications and validity of data generated during the study.
Exclusion Criteria
- •â€¢ Hypersensitivity reactions with murine proteins or planned chemotherapy •Diffuse lymphoma for which CHOP is not adequate therapy •Bulky Disease (10 cm on maximum dimension) or involves 1/3 of chest diameter (on radiographic imaging) •Need for emergency therapy such as neurologic compression syndrome •Subjects with CNS involvement or CNS lymphoma (Diffuse large B-cell lymphoma that is primary CNS, effusional, or intravascular according to the WHO, 2008 classification) •Patient treated with prior chemotherapy including not limited to Anthracyclines, Rituximab, anti-CD-20 therapy or autologous or allogeneic stem cell transplantation •Any radiotherapy given for lymphoma or non-lymphoma before 30 days of planned treatment •Symptomatic peripheral neuropathy (≥Grade 2,Common Terminology Criteria of Adverse Events [CTCAE v 4.03) •Patients using systemic antibiotic therapy 30 days prior to screening.
Outcomes
Primary Outcomes
Overall Response rate (ORR) by International Working Group (IWG) response criteria
Time Frame: At baseline, end of cycle 3 and 6.
Secondary Outcomes
- Pharmacodynamics: CD19 counts(Pharmacokinetics:Cmax, Tmax & AUC)
Investigators
Study Sites (36)
Loading locations...
Similar Trials
Unknown
Phase 1
Cilostazol-Simvastatin Drug Interaction StudyDyslipidemiasPeripheral Artery DiseaseNCT02431013Ajou University School of Medicine20
Completed
Phase 3
A phase-III clinical trial to study the effects of Azilsartan in Indian patients of hypertension.CTRI/2014/08/004840Hetero Labs Limited303
Completed
Phase 3
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell LymphomaLymphoma, Large B-Cell, DiffuseNCT01649856Hoffmann-La Roche572
Recruiting
Phase 3
Efficacy and safety study to assess between three drugs (Inhaler) in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2023/01/048668Lupin Limited278
Not yet recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastNCT03854617Chinese Academy of Medical Sciences172